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Gaucher disease (GD) is caused by mutations in the GBA1 gene, which encodes lysosomal 
β -glucocerebrosidase. Homozygosity for the L444P mutation in GBA1 is associated with high 
risk of neurological manifestations which are not improved by enzyme replacement therapy. 
Alternatively, pharmacological chaperones (PCs) capable of restoring the correct folding and 
trafficking of the mutant enzyme represent promising alternative therapies.Here, we report on 
how the L444P mutation affects mitochondrial function in primary fibroblast derived from GD 
patients. Mitochondrial dysfunction was associated with reduced mitochondrial membrane potential, 
increased reactive oxygen species (ROS), mitophagy activation and impaired autophagic flux.
Both abnormalities, mitochondrial dysfunction and deficient β -glucocerebrosidase activity, were 
partially restored by supplementation with coenzyme Q10 (CoQ) or a L-idonojirimycin derivative, 
N-[N’-(4-adamantan-1-ylcarboxamidobutyl)thiocarbamoyl]-1,6-anhydro-L-idonojirimycin (NAdBT-
AIJ), and more markedly by the combination of both treatments. These data suggest that targeting 
both mitochondria function by CoQ and protein misfolding by PCs can be promising therapies in 
neurological forms of GD.
Lysosomal storage diseases (LSDs) describe a heterogeneous group of rare inherited metabolic disor-
ders which result from the absence or loss of function of lysosomal proteins and characterized by the 
progressive accumulation of undigested material in lysosomes. The accumulation of substances affects 
the function of lysosomes and other organelles, resulting in secondary changes, such as impairment of 
autophagy, mitochondrial dysfunction and inflammation1, which ultimately results in cellular defects 
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and clinical abnormalities. LSDs frequently involve the central nervous system (CNS), where neuronal 
dysfunction or loss results in progressive motor degeneration and premature death.
Gaucher disease (GD), the LSD with the highest prevalence, is caused by mutations in the GBA1 gene 
that results in defective and insufficient activity of the enzyme β -glucocerebrosidase (GCase). Decreased 
catalytic activity and/or instability of GCase leads to accumulation of glucosylceramide (GlcCer) and 
glucosylsphingosine (GlcSph) in the lysosomes of macrophage cells and visceral organs. GD can be 
subdivided into 3 types based on age at onset and neurological manifestations. Gaucher patients without 
CNS involvement are classified as type I, while those with CNS involvement are type II or type III2. The 
disease manifests itself in a wide range of organ systems, with signs of hepatosplenomegaly, osteopenia, 
anemia, cardiopulmonary disease, or neurodegenerative syndromes. Neurological signs include ataxia, 
pyramidal signs, myoclonic epilepsy, or supra nuclear ophthalmoplegia3. Additionally, mutations in the 
GBA1 gene are a risk factor for Parkinson’s disease and other dementia with Lewy bodies4,5, as it appears 
that similar underlying defects in autophagy and mitochondrial dysfunction may link the pathophysiol-
ogy of these disorders6. Lysosomes are essential for autophagy, and autophagic clearance of dysfunctional 
mitochondria and represent an important element of mitochondrial quality control. Given that cellular 
quality control is essential to maintaining correct mitochondrial function, it can be inferred that dysfunc-
tion of this organelle in LSDs correlates with abnormal accumulation of mitochondria, mitochondrial 
dysfunction and a block of autophagy7.
Currently, enzyme replacement therapy (ERT) and small-molecule substrate reduction therapy (SRT) 
are the only approved treatment options for patients with the non-neurologic form of GD. ERT, based 
on the intravenous administration of recombinant GCase, is the effective treatment for type I GD. 
However, the CNS manifestations of type II and III GD do not respond well to ERT due to the inability 
of exogenous enzyme to cross the blood-brain barrier (BBB)8. SRT drugs have the potential for better 
CNS penetration and producing some neurological benefit as the therapeutic agent is a small molecule, 
such as N-butyl-1-deoxynojirimycin (NB-DNJ, Miglustat, Zavesca®), which acts as a weak inhibitor of 
glucosylceramide synthase, thus reducing the biosynthesis of GlcCer. Miglustat has been approved for 
use in patients with mild-to-moderate type I Gaucher disease, and is currently being evaluated in neu-
ronopathic Gaucher patients, though a recent report showed no significant benefit for the neurological 
manifestations of type III patients9. Furthermore, many patients treated with Miglustat have experienced 
side effects including diarrhea, weight loss, tremor, and peripheral neuropathy10.
More recently, pharmacological chaperone therapy (PCT) has been proposed as a potential treatment 
for GD11 . PCs are designed to selectively bind to and stabilize the folded state of a given LSD-associated 
enzyme in the endoplasmic reticulum (ER). In the case of GD, PCs are designed for facilitating proper 
folding, trafficking to lysosomes and function of the mutant GCase12. PCs also have the potential to 
attenuate the unfolded protein response and prevent ER stress that can lead to apoptosis and other 
inflammatory responses13. The fact that PCs are less expensive, can be given orally and usually cross the 
BBB, opens up the possibility of treating Type II and Type III GD patients with neurological involvement 
that are not responsive to ERT.
One of the most prevalent GD-causing mutations in humans is a L444P missense mutation in the 
GCase protein, which results in its disrupted folding in the ER and impaired post-ER trafficking. Patients 
homozygous for the L444P mutation usually display a more severe neurologic form of GD14. The fact that 
this mutation is located in a non-catalytic domain of GCase makes the protein particularly refractory 
to the rescuing action of active-site directed pharmacological chaperones, with only a few examples on 
record15–17. Evaluation of new bicyclic L-idonojirimycin derivatives related to the calystegine alkaloids18,19 
as PCs in human GD fibroblasts homozygous for the L444P mutation, let identify some representatives 
bearing potential therapeutic options for increasing GCase activity and enzyme trafficking to lysosomes 
in GD patients with the L444P/L444P genotype 20. These new chaperones belong to the sp2-iminosugar 
glycomimetics, characterized by a high selectivity among lysosomal glycosidases21,22, and can be prepared 
through efficient reaction sequences with relatively low synthetic cost23. One of the most promising 
candidates is N-[N’-(4-adamantan-1-ylcarboxamidobutyl)thiocarbamoyl]-1,6-anhydro-L-idonojirimycin 
(NAdBT-AIJ)20.
Likewise, as mitochondrial dysfunction and/or impaired mitochondria elimination may be associated 
to alterations of lysosome-dependent processes, coenzyme Q10 (CoQ), an antioxidant and mitochondrial 
energizer, is currently considered as a potential experimental drug for the treatment of neurodegener-
ative diseases in general24 and lysosomal diseases in particular25. We conceived that addressing both 
mutant GCase rescuing by NAdBT-AIJ as PC and mitochondrial function by CoQ might lead to bene-
ficial synergies.
The aim of our study was to assess mitochondrial dysfunction in Gaucher fibroblasts harboring 
the L444P mutant GCase and elucidate whether the single or combined treatments with CoQ and PC 
NadBT-AIJ were able to ameliorate their biochemical phenotype.
Results
Effect of CoQ and PC NAdBT-AIJ Supplementation on Mitochondrial Dysfunction in Gaucher 
Fibroblasts. To determine the presence of mitochondrial dysfunction in Gaucher fibroblasts harbor-
ing the L444P/L444P mutation, we first measured the activities of respiratory chain enzymes in control 
and patient (Gaucher A, B and C) fibroblasts. Complex I, II, III and II+ III activities were reduced by 
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~20% in Gaucher A, Gaucher B and Gaucher C fibroblasts respect to controls (Fig. 1a). Given the criti-
cal role of CoQ in mitochondria function, transferring reducing equivalents from complexes I and II to 
complex III, it has been suggested that CoQ levels could be a useful biological marker of mitochondrial 
function26. Therefore, we next assessed whether fibroblasts derived from the patients with GD were defi-
cient in CoQ. The average CoQ content of the three Gaucher fibroblasts cell lines was reduced by 24% 
relative to the average value of three control fibroblasts (Fig. 1b).
To assess the functional consequences of reduced respiratory chain enzyme activities and CoQ levels 
in Gaucher fibroblasts, we determined the mitochondrial membrane potential (Δ Ψ m) in both control 
and Gaucher fibroblasts by MitoTracker staining coupled with flow cytometry analysis. As shown in 
Fig 1c, Gaucher fibroblasts showed a significant reduction in Δ Ψ m, suggesting that the capacity to pro-
duce ATP may be diminished in Gaucher fibroblasts. Mitochondrial depolarization was also confirmed 
by measuring the ratio of TMRM (tetramethylrhodamine methyl ester) to MTG (MitoTracker Green 
FM) signal by flow cytometry (Supplementary Figure S1a).
Indeed, ATP levels were reduced to 30% of the control value in Gaucher fibroblasts (Fig.  1d). 
MitoTracker staining and imaging analysis of individual mitochondria confirmed the presence of normal 
tubular mitochondria (Fig.  1e,f,g, red arrow) along with a population of small rounded mitochondria 
with a striking depolarization (Fig. 1e,f,g; yellow arrow).
To elucidate whether bioenergetic impairment in Gaucher fibroblasts could be attenuated by improv-
ing mitochondrial function by CoQ and restoring GCase folding by PC administration, we quantified 
Δ Ψ m and ATP levels after CoQ (25 μ M), PC NAdBT-AIJ (25 μ M) or CoQ + PC (25 μ M + 25 μ M) sup-
plementation. Both CoQ or PC treatments and specially the combined treatment of CoQ + PC resulted 
in a significant increase in Δ Ψ m and cellular ATP levels in Gaucher fibroblasts, but it had no effect in 
control cells (Fig. 2b). CoQ + PC effectiveness in improving Δ Ψ m and ATP levels was confirmed in the 
three Gaucher cell lines (Supplementary Figure S1b and S1c).
Next, we determined the effect of the L444P/L444P GCase mutation on cellular proliferation, as an 
indicator of correct or altered cell homeostasis, after CoQ and/or PC treatments. Proliferation rate was 
increased in Gaucher fibroblasts after both CoQ or PC treatments, and more significantly under the 
combined treatment CoQ + PC (Fig. 2c).
Staining with MitoTracker Red and cytochrome c immunostaining revealed discrete staining of mito-
chondria in control cells, with mitochondria organized in a tubular network, whereas small, rounded 
depolarized mitochondria were observed in Gaucher fibroblasts (Supplementary Figure S2a and S2b). 
The fact that Mitotracker staining colocalized with cytochrome c, a mitochondrial marker, (Supplentary 
Figure S2a) confirmed the specificity of MitoTracker staining and verified that mitochondrial depo-
larization in Gaucher fibroblasts was not a result of cytochrome c release, as occurs in apoptosis27. 
Supplementation with CoQ (25 μ M) or PC NAdBT-AIJ (25 μ M) and specially the combined treatment of 
both CoQ + PC restored normal mitochondrial network and MitoTracker Red uptake in Gaucher fibro-
blasts, indicating restoration of Δ Ψ m (Figure 2Sa and 2Sb). Indeed, determination of GlcCer levels and 
Δ Ψ m in control and Gaucher fibroblast cultures after the incubation with conduritol B-epoxide (CBE), 
an irreversible inhibitor of GCase, or exogenous GlcCer unequivocally established that accumulation of 
GlcCer induced a decrease in Δ Ψ m (Supplementary Figure S3a, S3b and S3c), strongly suggesting that 
the effects of GlcCer accumulation extend beyond the lysosomal compartment and affect other cellular 
organelles such as mitochondria.
Effect of CoQ and PC NAdBT-AIJ on Reactive Oxygen Species (ROS) Production in Gaucher 
Fibroblasts. It is well established that mitochondrial dysfunction is associated with increased ROS 
production. Therefore, we examined mitochondrial ROS levels using the mitochondrial superoxide 
indicator MitoSOX Red in control and L444P Gaucher fibroblasts. At the same time, we estimated 
mitochondrial mass with 10-N-nonyl acridine orange (NAO) and determined the ratio of MitoSOX 
signal to NAO fluorescence. H2O2 levels were also measured using CMH2-DCFDA and flow cytome-
try analysis. Mitochondrial superoxide production and H2O2 levels were increased approximately by 
2.5-fold (Fig. 3a,b) and by 2-fold respectively, suggesting increased oxidative stress in Gaucher fibroblasts. 
Supplementation with CoQ (25 μ M), PC NAdBT-AIJ (25 μ M) and specially the combined treatment 
of both CoQ + PC induced a considerable reduction in mitochondrial superoxide and H2O2 levels in 
Gaucher cultures, but had no effect in control cultures (Fig. 3c,d). CoQ + PC effectiveness in reducing 
ROS levels was confirmed in the three Gaucher cell lines (Supplementary Figure S4).
Autophagy in Gaucher Fibroblasts. Recent evidence suggests the involvement of ROS in autophagy 
activation28. To determine if autophagy was increased in Gaucher L444P fibroblasts, we first measured 
the amount of acidic vacuoles by LysoTracker staining and fluorescence microscopy and flow cytometry 
analysis. Using this technique, a 1.4 fold increase in LysoTracker staining was observed in Gaucher as 
compared to control fibroblasts (Fig. 4a,b). To elucidate whether autophagy in Gaucher fibroblasts could 
be attenuated by improving mitochondrial function by CoQ and mutant GCase folding by NAdBT-AIJ 
chaperone supplementation, we quantified the number of lysosomes in the various cultures following 
CoQ (25 μ M), PC NAdBT-AIJ (25μ M) or CoQ + PC supplementation. Treatment was associated with 
a reduction in the intensity of LysoTracker staining in Gaucher fibroblasts (Fig.  4c), indicating that 
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Figure 1. Mitochondrial dysfunction in Gaucher fibroblasts. (a) Mitochondrial enzymatic activities of 
complex I, II, III and II+ III in control and Gaucher fibroblasts was determined as described in Materials 
and Methods. (b) CoQ levels in control and Gaucher fibroblasts were determined by hexane extraction and 
HPLC separation as described in Materials and Methods. (c) Mitochondrial membrane potential (Δ Ψ m) 
was assessed by flow cytometry using MitoTracker Red. A clear decrease of Δ Ψ m was observed in Gaucher 
fibroblasts. (d) ATP levels in control and Gaucher fibroblasts. A significant decrease of ATP levels was 
observed in Gaucher fibroblasts (e) Representative images of MitoTracker staining in control and Gaucher 
fibroblasts. Scale bar=15 μm. (f) Magnification of a small area in a Gaucher fibroblast. Red arrow indicates 
tubular mitochondria with normal polarization. Yellow arrow indicates small mitochondria with a striking 
depolarization in Gaucher fibroblasts. Scale bar=5 μm. (g) Quantification of depolarized mitochondria in 
control and Gaucher fibroblasts by fluorescence microscopy determined from 100 randomly selected cells 
by fluorescence imaging analysis. For control cells, the data are the mean± SD for experiments conducted 
on 3 different control cell lines. Data represent the mean± SD of 3 separate experiments. *p < 0.05 between 
control and Gaucher fibroblasts. **p < 0.01 between control and Gaucher fibroblasts.
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Figure 2. Mitochondrial function in Gaucher fibroblasts is recovered by CoQ and PC NAdBT-AIJ 
treatments. Control and Gaucher-B fibroblasts were cultured in the absence or presence of CoQ (25 μ M), 
PC NAdBT-AIJ (25 μ M) or CoQ + PC (25 μ M + 25 μ M) for 96 h. (a) Mitochondrial membrane potential 
(Δ Ψ m) in control and Gaucher fibroblasts. Δ Ψ m was assessed by flow cytometry using MitoTracker Red 
staining. (b) Adenosine-5’-triphosphate (ATP) levels in control and Gaucher fibroblasts. (c) Cell proliferation 
of control and Gaucher fibroblasts. For the control cells the data are the means± SD of three different control 
cell lines. Data represent the mean± SD of 3 separate experiments. *p < 0.01 between control and Gaucher 
fibroblasts. ap < 0.05 between the presence and the absence of CoQ. bp < 0.05 between the presence and the 
absence of PC. cp < 0.05 between the presence and the absence of CoQ+ PC. #p < 0.05 between CoQ+ PC 
and CoQ or PC treatment.
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Figure 3. ROS production in Gaucher fibroblasts. (a) Mitochondrial ROS levels in control and Gaucher 
fibroblasts. Results are expressed as the ratio of MitoSOX signal to 10-N-nonyl acridine orange signal. (b) 
H2O2 levels in control and Gaucher fibroblasts by CMH2-DCFDA staining coupled with flow cytometry 
analysis. (c) Mitochondrial ROS levels in control and Gaucher-B fibroblasts cultured, in the absence or 
presence of CoQ (25 μ M), PC NAdBT-AIJ (25 μ M) or the combination of both CoQ + PC (25 μ M + 25 μ M) 
for 96 h. (d) H2O2 levels in control and Gaucher-B fibroblasts cultured, in the absence or presence of CoQ 
(25 μ M), PC NAdBT-AIJ (25 μ M) and the combination of both CoQ + PC (25 μ M + 25 μ M) for 96 h. The 
mean ± SD of 3 independent experiments are showed. *p < 0.01 between control and Gaucher fibroblasts. 
ap < 0.05 between the presence and the absence of CoQ. bp < 0.05 between the presence and the absence of 
PC. cp < 0.05 between the presence and the absence of CoQ + PC. #p < 0.05 between CoQ + PC and CoQ or 
PC treatment.
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Figure 4. Increased expression of autophagic markers in Gaucher fibroblasts. (a) Quantification of 
acidic vacuoles in control and Gaucher fibroblasts by LysoTracker staining and flow cytometry analysis. 
(b) Representative LysoTracker staining images in control and Gaucher fibroblasts. Scale bar= 15 μm. (c) 
Effect of CoQ, PC and CoQ + PC on the amount of acidic vesicules in Gaucher-B fibroblasts. Control and 
Gaucher fibroblasts were cultured in the presence or absence of CoQ (25 μ M), PC NAdBT-AIJ (25 μ M) 
or CoQ + PC (25 μ M + 25 μ M) for 96 h. Acidic vacuoles were quantified by LysoTracker staining and flow 
cytometry analysis. For control cells, the data are the mean ± SD for experiments conducted on 2 different 
control cell lines. Data represent the mean ± SD of 3 separate experiments. *p < 0.01 between control and 
Gaucher fibroblasts. ap < 0.05 between the presence and the absence of CoQ. bp < 0.05 between the presence 
and the absence of PC. cp < 0.05 between the presence and the absence of CoQ + PC. #p < 0.05 between 
CoQ + PC and CoQ or PC treatment. (d) The expression levels of LC3-I (upper band) and LC3-II (lower 
band), ATG12, BECLIN1 and cathepsin D were determined in the control and Gaucher-B fibroblast cultures 
by Western blotting. The ATG12 band represents the Atg12-Atg5 conjugated form. Fibroblast cultures 
were grown in normal culture medium or in medium supplemented with CoQ (25 μ M), PC (25 μ M) or 
the combination of both CoQ + PC (25 μ M + 25 μ M) for 96 h. Actin was used as a loading control. The 
densitometric analysis of Western blottings is showed in Supplementary Figure S6.
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lysosomal activity was reduced following CoQ or PC supplementation and more significantly with the 
combined treatment CoQ + PC. CoQ + PC effectiveness in reducing the amount of acidic vacuoles was 
confirmed in the three Gaucher cell lines (Supplementary Figure S5a and S5b).
To further verify that autophagy was activated in Gaucher fibroblasts, we examined the expression 
levels of autophagic and lysosomal proteins by Western blotting. First, we investigated the conversion 
of LC3-I (microtubule-associated light chain3) to LC3-II, which is closely correlated with the num-
ber of autophagosomes. The ratio of LC3-II to LC3-I was significantly increased in Gaucher fibroblasts 
(Fig. 4d), indicating enhanced autophagosome formation in Gaucher fibroblasts. As autophagosome for-
mation involves an ubiquitin-like conjugation system in which Atg12 is covalently bound to Atg5, we 
also determined the expression levels of ATG12-ATG5 conjugates. ATG12-ATG5 expression levels were 
significantly increased in Gaucher fibroblasts. Likewise, the expression levels of BECLIN1, another essen-
tial protein required for the initiation of the formation of the autophagosome, was slightly increased in 
Gaucher fibroblasts when compared to control cells (Fig. 4d). We also studied autophagy activation in 
Gaucher fibroblasts by examining the expression levels of cathepsin D, a lysosomal enzyme. Compared to 
control cultures, there was a significant increase in cathepsin D expression levels in Gaucher fibroblasts. 
Supplementation with CoQ (25 μ M) or PC NAdBT-AIJ (25 μ M) partially reduced the expression levels 
of autophagic and lysosomal proteins (Fig.  4d). However, the combined treatment of both CoQ + PC 
was highly effective and restored the autophagic and lysosomal protein expression levels to near control 
levels (Fig. 4d). The densitometric analysis of Western blottings is showed in Supplementary Figure S6.
Mitophagy in Gaucher Fibroblasts. To determine whether selective mitochondrial degradation 
or mitophagy was increased in Gaucher fibroblasts, we performed immunofluorescence double stain-
ing with antibodies against LC3 (autophagosome marker) and cytochrome c (mitochondrial marker) 
(Fig. 5a,b,c). LC3 staining was hardly detectable in control cells (Fig. 6a), whereas normal tubular mito-
chondria, negative for LC3, along with many small, fragmented mitochondria, positive for LC3, were 
observed in Gaucher fibroblasts (Fig. 5a,b,c). The population of small, rounded mitochondria showed a 
high colocalization of cytochrome c with LC3 staining, (r = 0.8929), whereas the tubular mitochondria 
did not (r = 0.0526) (Fig. 5a,b,c).
Supplementation with CoQ (25 μ M) or PC NAdBT-AIJ (25 μ M) partially reduced the number of 
LC3/cytochrome c punctata (Fig. 5c). However, the combined treatment of both CoQ+ PC, was highly 
effective and drastically reduced the number of LC3/cytochrome c punctata (Fig. 5c).
Mitophagy activation in Gaucher fibroblasts was also confirmed by checking that the expression levels 
of mitochondrial proteins such as complex I (30 kDa subunit), complex III (core 1 subunit), and porin 
were reduced compared to controls fibroblasts and, on the contrary, the expression levels of Golgi (Golgi 
marker), endoplasmic reticulum (PDI, protein disulfide isomerase), and peroxisome (catalase) proteins 
markers were not affected (Fig.  6a). Supplementation with CoQ (25 μ M) or PC NAdBT-AIJ (25 μ M) 
partially restored mitochondrial protein expression levels (Fig.  6a). However, the combined treatment 
of both CoQ + PC was highly effective and mitochondrial protein expression levels were increased near 
to control values (Fig. 6a). The densitometric analysis of Western blottings is showed in Supplementary 
Figure S7.
Autophagic Flux is Impaired in Gaucher Fibroblasts. To examine autophagosome/autophagolys-
osomal maturation and to ascertain whether or not the autophagic flux is impaired in Gaucher fibro-
blasts, we also checked the levels of LC3-II in the presence of bafilomycin A1 (Baf), a specific inhibitor 
of vacuolar H+-ATPases and a blocker of autophagosome-lysosome fusion. As expected, bafilomycin A1 
treatment in control fibroblast cells led to a significant increase in the amount of LC3-II, suggesting that 
autophagic flux was normal (Fig. 6b,c). However, bafilomycin A1 treatment in Gaucher fibroblasts had 
no effect on LC3-II expression levels (Fig.  6b,c), indicating that autophagic flux was impaired in this 
case. We also examined whether mitochondrial proteins levels were affected by inhibition of autophagic 
flux. Inhibition of autophagosome-lysosome fusion by bafilomycin A1 induced an increase of porin and 
cytochrome c levels in Gaucher fibroblasts but not in control fibroblasts (Fig. 6a,b), suggesting increased 
mitochondrial delivery and degradation within autophagolysosomes in mutant cells.
Altogether, these results support the hypothesis that both mitophagy activation and impaired auto-
phagic flux coexist in Gaucher fibroblasts.
Autophagy is a Protective Mechanism in Gaucher Fibroblasts. To verify the role of autophagy in 
survival of GCase deficient cells, apoptosis was examined in GCase deficient wild-type and Atg5-/- mouse 
embryonic fibroblasts (MEFs). GCase deficiency in MEFs was produced by treatment with the specific 
GCase inhibitor CBE. We verified that CBE treatment indeed induced GCase deficiency in wild-type 
and Atg5-/- knockout fibroblasts (data not shown). We then analyzed cell viability and apoptosis in 
both GCase-deficient wild-type and knockout fibroblasts. GCase deficiency induced a high viability and 
low level of apoptosis in wild-type MEFs as determined by detecting caspase activation, cytochrome c 
release, and nuclear DNA condensation. In contrast, Atg5-/- MEFs were significantly more sensitive to 
GCase deficiency induction with a significant decrease in cell viability and a 1.5 fold increase in apoptosis 
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Figure 5. Autophagosome and mitochondria markers colocalization in Gaucher fibroblasts. (a) Image 
analysis of LC3 and cytochrome c immunostaining in control and Gaucher fibroblasts. Control and 
Gaucher-B fibroblasts were cultured in the presence or absence of CoQ (25 μ M), PC NAdBT-AIJ (25 μ M) or 
CoQ + PC (25 μ M + 25 μ M) for 96 h. Cells were fixed and immunostained with anti-LC3 (autophagosome 
marker) and cytochrome c (mitochondrial marker) and examined by fluorescence microscopy. Scale 
bars=15 (upper and lower pannel) or 5 μm (middle pannel). (b) Magnification of a small area in a Gaucher 
fibroblast. Yellow arrow shows autophagosomes with LC3 and cytochrome c colocalization. Red arrow 
shows tubular mitochondria without colocalization with LC3. Colocalization of both markers was assessed 
using the DeltaVision software and calculating the Pearson´s coefficient of correlation. Scale bar = 5 μ m. 
(c) Quantification of LC3/cytochrome c puntacta in control and Gaucher fibroblasts incubated with or 
without CoQ, PC and CoQ+ PC (n = 100 cells).*p < 0.01 between control and Gaucher fibroblasts. ap < 0.05 
between the presence and the absence of CoQ. bp < 0.05 between the presence and the absence of PC. 
cp < 0.05 between the presence and the absence of CoQ + PC. #p < 0.05 between CoQ + PC and CoQ or PC 
treatment.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:10903 | DOi: 10.1038/srep10903
Figure 6. Mitophagy and impaired autophagic flux in Gaucher fibroblasts. (a) Western blot analysis of 
mitochondrial (complex I, 30 kDa subunit; complex II, 30 kDa subunit; complex III, core 1 subunit; complex 
IV, COX II subunit; and porin), Golgi (Golgi marker), endoplasmic reticulum (PDI), and peroxisome 
(catalase) proteins in control and Gaucher-B fibroblasts treated with CoQ (25 μ M), PC NAdBT-AIJ (25 μ M) 
or CoQ + PC (25 μ M+ 25 μ M) for 96 h. Alpha-tubulin was used as loading control. (b) Autophagy flux. 
Determination of LC3-II, porin and cytochrome c levels in the presence and absence of bafilomycin A1 in 
control and Gaucher-B fibroblasts. Control and Gaucher fibroblasts were incubated with bafilomycin A1 
(100 nM for 12 h). Total cellular extracts were analyzed by immunoblotting with antibodies against LC3, 
porin and cytochrome c. α -Tubulin was used as a loading control. (c) Densitometry of Western blotting 
was performed using the ImageJ software. Data represent the mean ± SD of three separate experiments. 
*p < 0.01 between control and Gaucher fibroblasts. ap < 0.05 between the presence and the absence of 
bafilomycin A1. (d) Apoptosis is increased in GCase-deficient Atg5-/- cells. Apoptosis is increased in GCase-
deficient Atg5-/- cells. GCase deficiency in wild-type and Atg5-/- MEFs was induced by treatment with 
CBE 2,5 mM for 48 hours. Apoptosis was assessed in both autophagy proficient (wild-type), and autophagy-
deficient cells (Atg5-/-) treated with CBE as described in Material and Methods. CBE-treated MEFs were 
also supplemented with, CoQ+ PC NAdBT-AIJ for 96 hours to verify the specificity of apoptosis induction 
by GCase deficiency. Results are expressed as mean ± SD of three independent experiments *p < 0.01 
between Atg5-/- and wild-type MEFs. ap < 0.01 between the presence and the absence of CBE . bp < 0.01 
between Atg5-/- in the presence or absence of CoQ+ PC.
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respect to wild-type cells (Fig. 6d). CoQ+ PC supplementation of CBE-treated MEFs reduced cell death 
to control values, confirming the specificity of apoptotic induction by GCase deficiency (Fig. 6d).
Treatment with CoQ+PC NAdBT-AIJ Increases GCase Activity, Improves Enzyme Traffic and 
Reduces Intracellular GlcCer Levels. GCase activities in the three Gaucher fibroblasts cell lines 
were reduced to 10%, 8% and 6% respectively, compared to control values (Supplementary Figure S8a). 
To elucidate whether GCase activities could be restored by improving mitochondrial function by CoQ 
and protein folding of the mutant GCase by PC NAdBT-AIJ supplementation, we determined GCase 
activities after treatment with CoQ (25 μ M), PC NAdBT-AIJ (25 μ M) or CoQ + PC. Supplementation 
with CoQ, PC and specially the combination of CoQ + PC induced a significant increase of 2-fold, 
2.4-fold and 3.4-fold, respectively, of GCase activities (Fig.  7a). CoQ + PC treatment effectiveness in 
improving GCase activity was also confirmed in the three Gaucher cell lines (Supplementary Figure S8b).
Furthermore, deficient GCase activities were associated with reduced levels of GCase in Gaucher 
fibroblasts (Fig. 7b,c). As expected, both CoQ or PC and more significantly CoQ + PC treatment induced 
a marked increase in GCase expression levels (Fig. 7b,c).
Accordingly, CoQ + PC treatment was also able to facilitate the efficient translocation of the mutant 
GCase to the lysosome compartment in Gaucher fibroblasts. The intracellular localization of mutant 
GCase before and after treatment was determined by using indirect fluorescent immunostaining. Cells 
were co-stained with IgGs against GCase and either a marker for lysosomes (LAMP-1) or an ER marker 
(PDI) (Fig. 8a,b). In untreated cells, GCase staining was diffuse and distinct from the punctate staining 
pattern of LAMP-1 (Fig. 8b). Instead, GCase staining colocalized (indicated by yellow colour) with the 
ER marker PDI (Fig.  8a). However, when Gaucher fibroblasts were treated with CoQ co-administered 
with PC NAdBT-AIJ, their GCase staining pattern increased in fluorescence intensity, became more 
punctate and exhibited a greater co-localization with LAMP-1, as indicated by the increased yellow col-
our in the Merge column (Fig. 8b). Furthermore, there was a notable decrease in the overlap between 
GCase and PDI staining of cells treated with CoQ + PC (Fig. 8a). In the case of CoQ + PC-treated cells, 
there was also an observable decrease in the overall intensity level of PDI staining, suggesting a decrease 
in ER stress, for which PDI is also a marker, as compared to untreated cells (Fig. 8a).
To verify increased mutant GCase folding and trafficking from the ER to the lysosomes, we performed 
endoglycosidase H (Endo-H) digestion assay on cell lysates from control and Gaucher fibroblasts, as it 
has been previously reported15. ER retained GCase proteins carrying N-linked glycans which are sensitive 
to Endo-H cleavage, producing a low molecular weight band of GCase on Western blotting (Endo-H-S).
In control fibroblasts most of GCase was Endo-H resistant (Endo-H-R), indicating that the protein 
passed already the mid-Golgi (probably mature lysosomal) (Fig. 8c,d). On the other, a lesser amount of 
the enzyme were Endo-H-R in Gaucher fibroblasts, suggesting that a significant fraction of GCase in 
these cells did not reach the mid-Golgi and therefore was not lysosomal. The increased levels of mutant 
GCase protein Endo-H-R in response to treatments, particularly CoQ + PC, support the hypothesis of a 
partial restoration of mutant GCase folding and post-ER trafficking.
Furthermore, to confirm the effectiveness of PC and/or CoQ treatment in improving Gcase activity, 
we quantified GlcCer levels by Dot-blot assays in control and Gaucher fibroblasts after CoQ (25 μ M), PC 
NAdBT-AIJ (25 μ M) or CoQ + PC (25 μ M + 25 μ M) supplementation. Both CoQ and PC and specially 
the combined treatment of CoQ+ PC resulted in a significant reduction in GlcCer levels in Gaucher 
fibroblasts (Supplementary Figure S9a and S9b). Fluorescence microscopy examination also confirmed 
that CoQ + PC treatment reduced GlcCer accumulation both in the lysosomal and mitochondrial com-
partment (Supplementary Figure S10).
Discussion
In this work, we studied the pathophysiology of the L444P/L444P mutation in primary cultured fibro-
blasts derived from GD patients with neurological involvement. We assessed both GCase deficiency and 
mitochondrial function in cultured fibroblasts. We found mitochondrial dysfunction associated with 
reduced activity and expression levels of GCase in Gaucher fibroblasts. In addition, mitophagy activation 
as a mechanism to eliminate dysfunctional mitochondria and impaired autophagic flux were observed in 
Gaucher fibroblasts. Next, we evaluated the effects of treatments targeting mitochondrial dysfunction and 
GCase misfolding on the improvement of the pathophysiological alterations of GD. Coenzyme Q10 (CoQ), 
a commercially available 1,4-benzoquinone derivative with cellular energy production and antioxidant 
functions occurring naturally in most eukaryotic cells, and N-[N’-(4-adamantan-1-ylcarboxamidobutyl)
thiocarbamoyl]-1,6-anhydro-L-idonojirimycin (NAdBT-AIJ), a synthetic sp2-iminosugar-type PC 
recently shown to be active in restoring L444P GCase folding and trafficking in GD fibroblasts20, respec-
tively, were used for those purposes. Our results showed that although single treatments are partially 
effective, the combined treatment of both CoQ and PC markedly increased GCase activity and enzyme 
trafficking to the lysosomes, and also improved mitochondrial function and the associated pathophysi-
ological alterations.
Interestingly, the amount of CoQ, an essential electron carrier of the mitochondrial respiratory chain, 
was reduced in Gaucher fibroblasts. Concomitantly, a large proportion of the mitochondrial population 
was depolarized. Both alterations may further compromise normal mitochondrial function and cellular 
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Figure 7. Treatment of Gaucher fibroblasts with CoQ and PC NAdBT-AIJ increases GCase activity. 
(a) GCase activities in control and Gaucher-B fibroblasts cultured in the absence or presence of CoQ 
(25 μ M), PC NAdBT-AIJ (25 μ M) and CoQ + PC (25 μ M + 25 μ M) for 96 h. GCase activities increase after 
CoQ, PC and markedly after CoQ+ PC supplementation. Data, expressed as Gcase activity (% of control), 
represent the mean ± SD of 3 separate experiments. (b) GCase expression levels determined in control 
and Gaucher-B fibroblasts by Western blotting. Control and Gaucher fibroblast cultures were grown in 
normal culture medium or in medium supplemented with CoQ, PC and CoQ + PC for 96 h. Fibroblast 
protein extracts (50 μ g) were separated on a 12.5% SDS-polyacrylamide gel and immunostained with an 
antibody against GCase. Α-Tubulin was used as a loading control. (c) Densitometric analysis of Western 
blottings. Data represent the mean ± SD of 3 separate experiments. *p < 0.01 between control and Gaucher 
fibroblasts. ap < 0.05 between the presence and the absence of CoQ. bp < 0.05 between the presence and the 
absence of PC. cp < 0.05 between the presence and the absence of CoQ + PC. #p < 0.05 between CoQ + PC 
and CoQ or PC treatment.
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Figure 8. Treatment with CoQ and PC NAdBT-AIJ changes the intracellular localization of GCase in 
Gaucher fibroblasts. Effects of CoQ and PC NAdBT-AIJ on the traffic of GCase from the ER to lysosomes 
in Gaucher-B fibroblasts. Gaucher fibroblasts were treated with CoQ + PC (25 μ M + 25 μ M. (a) ER 
marker, PDI, or GCase are visualized as red or green, respectively. In the merged images, yellow denotes 
colocalization in the ER. Scale bar= 15 μ m. (b) Lysosomal marker, LAMP-1, or GCase are visualized as red 
or green, respectively. In the merged images, yellow denotes colocalization in lysosomes. Colocalization 
of both markers was assessed using the DeltaVision software and calculating the Pearson´s coefficient of 
correlation. Scale bar = 15 μ m. (c) Representative Western blots of cell lysates treated with Endo-H. Cell 
lysates from control and Gaucher fibroblasts treated with CoQ, PC and CoQ + PC were subjected to Endo-H 
digestion and Western blot analysis with anti GCase antibody. Note the appearance, after Endo-H treatment, 
of a low molecular weight band in Gaucher disease samples (grey arrow), which represents endoplasmic 
reticulum retained GCase protein (Endo-H-S) and a high molecular weight band (Endo-H-R) which 
represents mature GCase (black arrow). GAPDH was used as a loading control. (d) Densitometric analysis 
of Western blotting. Quantification of Endo H assay using ImageJ analysis software. The gray portion of each 
bar represents Endo H-S bands and the black portion of the bar represents Endo H-R bands.
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energy metabolism, which can aggravate the lysosomal functional defect. CoQ deficiency has been identi-
fied in a wide range of diseases, including mitochondrial diseases, lysosomal diseases, neurodegenerative 
diseases, such as Parkinson’s disease, cancer, fibromyalgia, and in patients undergoing statin treatment29.
In addition to CoQ deficiency and decreased mitochondrial membrane potential, we identified 
increased ROS production and H2O2 content, as well as increased expression of autophagic proteins. All 
these pathological conditions could be significantly ameliorated by CoQ + PC treatment in fibroblasts 
harboring the L444P/L444P mutation.
An alteration of autophagy in GD has been previously postulated30. GCase deficiency leads to both 
an induction of autophagy and an impairment of autophagic flux leading to accumulation of autophago-
somes and autophagic substrates. The impairment in degradation of autophagic substrates may contrib-
ute to several aspects of Gaucher neuropathology, including the accumulation of ubiquitinated proteins 
and ROS production. Thus, oxidative stress may play a prominent role in the induction of the mito-
chondrial damage and autophagy activation, which we observed in Gaucher fibroblasts. In addition, the 
elimination of dysfunctional mitochondria could play a crucial role in protecting cells from the damage 
caused by perturbed mitochondrial function. Our finding that the autophagic protein LC3 colocalized 
with structurally abnormal mitochondria, but not with normal tubular mitochondria in Gaucher fibro-
blasts, suggests that autophagy specifically targets dysfunctional mitochondria in these cells. Formerly 
reported evidences on several LSDs showed increased ROS, dysfunctional mitochondria, blocked auto-
phagy, aberrant inflammatory and apoptotic signaling and perturbed calcium homeostasis, among other 
biochemical alterations1.
Besides mitophagy activation, we found impaired autophagic flux in Gaucher fibroblasts. In GD, a 
reduction of autophagic flux may have a major impact on mitochondrial function and on cytoplas-
mic proteostasis. Constitutive macroautophagy maintains mitochondrial quality by selectively degrading 
dysfunctional mitochondria by mitophagy31. Mitochondrial proteins are consistently found in the pro-
teomes of highly purified autolysosomes, especially subunits of the mitochondrial ATPase32. Reduced 
autophagic flux in GD may lead to the persistence of dysfunctional mitochondria, which is highly pro-
nounced in other LSDs cells such as Batten’s disease neurons33. Several LSDs (mucolipidosis types IV, 
IIIA [pseudo-Hurler polydystrophy], and II [I-cell disease], late infantile neuronal ceroid lipifuscinosis 
[CLN2], mucopolysaccharidosis VI, and GM1 gangliosidosis) also display mitochondrial abnormalities, 
including replacement of the extended tubular mitochondrial network with high numbers of relatively 
rounded depolarized mitochondria1. Studies into aging and autophagosome formation have shown that 
mitochondria are involved in signaling pathways regulating apoptosis and innate immunity, and that 
reduced autophagic flux and subsequent accumulation of dysfunctional, reactive oxygen species–gener-
ating mitochondria renders cells more sensitive to apoptotic and inflammatory stimuli34. Therefore, the 
aberrant functioning of mitochondria may be responsible for apoptosis and inflammation in the CNS of 
multiple LSDs, including GD.
Defective activity of GCase in GD results in intracellular accumulation of the glycosphingolipids, 
glucosylceramide (GlcCer) and psychosine. Recently, it has been demonstrated in a mouse model of 
neuronopathic GD that glucosylceramide (GlcCer) and psychosine accumulation in GD brains precede 
the appearance of neuroinflammation, although only GlcCer accumulation correlated with neuroinflam-
mation and neuron loss35. Some authors have hypothesized that variations in lipids involved in ceramide 
metabolism, including both GlcCer and ceramide, might play an important role in the associated mito-
chondrial dysfunction in GD. The possible deleterious effect of glycosphingolipids in the mitochondrial 
membrane and cellular bioenergetics was already discussed by Strasberg et al.36 and it has been sug-
gested that the accumulation of the GlcCer and and GlcSph is the basis for the extensive neuronal cell 
loss in the neuronopathic forms GD type II/III35,37. Furthermore, it has been reported that the sphin-
golipid ceramides provoke oxidative stress by disrupting mitochondria and induce lethal mitophagy38. 
Interestingly, sub-cellular fractionation studies of Gaucher fibroblasts showed that GlcCer was not con-
fined to the lysosomes but its concentration increases throughout the cell39. In agreement with these 
results, we found that GlcCer is accumulated mainly in the lysosomal and mitochondrial compartments 
in Gaucher fibroblasts. We propose that both accumulation of GlcCer and impairment of autophagic flux 
induce mitochondrial dysfunction in Gaucher fibroblast. Dysfunctional mitochondria are involved in the 
pathogenesis of several neurodegenerative diseases, but the experimental evidence for a role in altered 
mitochondria dynamics is especially strong in PD6. The proper elimination of damaged mitochondria is 
needed in post-mitotic neurons because progressive accumulation of damaged mitochondria might lead 
to eventual cell death.
Mitochondrial dysfunction with reduced respiratory chain complex activities, increased ROS produc-
tion and decreased potential in neurons and astrocytes has recently been reported in a mouse model 
of type II neuronopathic Gaucher disease37. Thus, a primary lysosomal defect may cause accumulation 
of dysfunctional mitochondria. The neurological and pathological symptoms observed in Gaucher dis-
ease patients are similar to those displayed in Parkinson’s disease, including loss of dopaminergic neu-
rons in the substantia nigra, alpha-synuclein accumulation, tremors at rest, bradykinesia, and rigidity6. 
Indeed, parkinsonism has been reported in many Gaucher disease patients, suggesting a mechanistic 
link between the two disease states. Further supporting this, large, multicenter genome-wide association 
studies have reported a high incidence of GBA mutations in patients with sporadic Parkinson’s disease 
and an increased risk of developing Parkinson’s disease in GBA carriers40.
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An emerging strategy for the treatment of LSDs is pharmacological chaperone therapy (PCT), based 
on the use of chaperone molecules that assist the folding of mutated enzymes and improve their stability 
and lysosomal trafficking41. These PC can cross the BBB and therefore have a potential for the treatment 
of diseases with CNS involvement42. Our findings confirmed previous results showing the effectiveness 
of bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of 
Gaucher disease20. The PC compound NAdBT-AIJ increased GCase activity and also facilitated translo-
cation of the enzyme to the lysosome in Gaucher fibroblasts harboring the L444P mutation.
Likewise, given that defects in energy metabolism and oxidative stress have been demonstrated to 
play a role in the pathogenesis of GD, we envisioned that the treatment with coenzyme CoQ could also 
exert beneficial therapeutic effects. The fundamental role of CoQ in mitochondrial bioenergetics and its 
well-acknowledged antioxidant properties constitute the basis for its clinical applications, although some 
of its effects may be related to a gene induction mechanism29. Interestingly, CoQ is also able to cross 
the BBB43. Therefore, the combined treatment of CoQ with PC NAdBT-AIJ may represent a therapeutic 
strategy, supplementary or alternative to ERT in Gaucher patients with CNS involvement. Indeed, our 
results suggest that the combined treatment of CoQ with PC NAdBT-AIJ is high effective in improving 
the biochemical phenotype in cellular models of GD harboring the L444P/L444P mutation.
In summary, our studies provide experimental evidence that targeting mitochondrial dysfunction 
and GCase misfolding by the combined supplementation of CoQ and the L444P-active pharmacological 
chaperone NAdBT-AIJ could be beneficial in the treatment of patients with neuronopathic GD. However, 
additional experiments in neuronal or animal models are essential for the confirmation of these results.
Our findings support the hypothesis that secondary mitochondrial dysfunction by GlcCer accumu-
lation aggravates the effects of the L444P/L444P mutation and therefore, the improvement of mitochon-
drial function by CoQ treatment also improves the activity of the mutant GCase. The fact that both 
CoQ and PC NAdBT-AIJ can cross the BBB makes them promising candidates for the treatment of 
neuronopathic forms of GD that are not responsive to ERT.
Material and Methods
Reagents. Monoclonal Anti-Actin antibody, rabbit anti-VDAC1/Porin, rabbit anti-BECLIN1 
and 4-methylumbelliferyl β -D-glucopyranoside substrate were all obtained from Sigma- Aldrich (St. 
Louis, MO). Monoclonal antibodies against complex III (core 1 subunit) and complex I (30 kDa sub-
unit), Mitosox Red, CMH2-DCFDA, 10-N-nonyl acridine orange (NAO), MitoTracker, LysoTracker, 
tetramethylrhodamine methyl ester (TMRM), MitoTracker Green FM (MTG) and Hoechst 33342 were 
obtained from Invitrogen/Molecular Probes (Eugene, OR). Anti-GCase was obtained from Abcam. 
Anti-cytochrome c antibody was obtained from BD Biosciences Pharmingen (San Jose, CA) and 
anti-GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) monoclonal antibody (clone 6 C5) was from 
Calbiochem-Merck Chemicals Ltd. (Nottingham, UK). Anti-hATG12 and anti-hATG5 were obtained 
from Biosensis (South Australia, Australia). Conduritol-B-epoxide (CBE), Anti-MAP LC3 (N-20), 
anti-catalase (H-300), anti-PDI (H-160), anti-Golgi marker (AE-6), anti-Cathepsin D and anti-LAMP-1 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Protease inhibitors were obtained from 
Boehringer Mannheim (Indianapolis, IN). All other chemicals were purchased from Sigma-Aldrich. 
The anti-GlcCer rabbit anti-serum was purchased from Glycobiotech GmbH (Kükels, Germany). 
Glucocerebrosides from Gaucher’s spleen (GlcCer) was obtained from Matreya LCC (Pleasant Gap, PA, 
USA). Endoglycosidase-H was obtained from New England Biolabs (Hitchin, UK).
Fibroblast Cultures. Cultured fibroblasts from 3 Gaucher patients (Gaucher-A, Gaucher-B and 
Gaucher-C) homozygous for L444P GCase were obtained from Coriell Cell Repositories (Camden, NJ, 
USA). Control primary fibroblasts were obtained from healthy volunteers; any control value represent 
the mean value for at least two control fibroblasts cell lines. Samples from patients and controls were 
obtained according to the Helsinki Declarations of 1964, as revised in 2001. This study has been approved 
by the institutional ethical committee of Pablo de Olavide University. Informed consent was obtained 
from all subjects biopsied. Control and Gaucher fibroblasts were cultured at 37 °C in Dulbecco’s Modified 
Eagle Medium (DMEM) (4.5 g/L glucose), plus pyruvate supplemented with 20% fetal bovine serum 
(FBS), and an antibiotic/anti-mycotic solution.
Mouse Embryonic Fibroblasts (MEFs) derived from wild-type and Atg5-/- mouse embryos were a 
kind gift of Noboru Mizushima, Tokyo Medical and Dental University, Japan44.
Synthesis of the Pharmacological Chaperone NAdBT-AIJ. The preparation of the PC 
NAdBT-AIJ was accomplished in two steps and 95% overall yield from 5-amino-5-deoxy-
1,2-O-isopropylidene-β -L-idofuranose, which at its turn is readily accessible from commercial 
D-glucuronolactone, by nucleophilic addition of 4-(1-adamantanylcarboxamido)butyl isothiocyanate45 
followed by acid-catalyzed acetonide hydrolysis of the resulting thiourea adduct, following the procedure 
previously reported20.
Treatment of Fibroblasts Cell Lines. Cells were also cultured with or without 25 μ M CoQ and/
or 25 μ M PC NAdBT-AIJ for 96 h. CoQ and PC NAdBT-AIJ concentrations were selected based on the 
optimal concentration in increasing GCase activity in Gaucher fibroblasts.
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Mitochondrial Respiratory Chain and Citrate Synthase Enzyme Activities. Activities of 
Activities of NADH:coenzyme Q1 oxidoreductase (complex I), succinate dehydrogenase (complex 
II), ubiquinol:cytochrome c oxidoreductase (complex III), succinate:cytochrome c reductase (complex 
II+ III) and citrate synthase (CS) were determined in sonicated permeabilized fibroblasts using previ-
ously described spectrophotometric methods46. Results are expressed as % of activity respect to control 
values. Proteins of fibroblasts homogenates were analyzed by the Lowry procedure47.
Measurement of CoQ Levels. CoQ levels in cultured fibroblasts were performed using a method 
previously described by our group48.
Adenosine-5’-Triphosphate Levels. Adenosine-5’-triphosphate (ATP) levels were determined using 
a bioluminescence assay (ATP determination kit, Invitrogen- Molecular Probes, Eugene, OR).
Proliferation Rate. Two hundred thousand cells were cultured with or without 25 μ M CoQ and/or 
25 μ M PC for 96 h. Cell counting was performed from 10 high power fields using an inverted microscope 
and a 40× objective.
GCase Activity Assay. GCase activities in cell lysates were determined by using 
4-methylumbelliferone-conjugated β -D-glucopyranoside as a substrate. The lysates (10 μ L) were incu-
bated at 37 °C with the substrate solution (20 μ L) in 0.1 M citrate buffer, pH 5.2, supplemented with 
sodium taurocholate (0.8% w/v) for 1 h. The reactions were terminated by adding 0.2 μ L of 0.2 M glycine 
sodium hydroxide buffer (pH 10.7). The liberated 4-methylumbelliferone was measured spectrophoto-
metrically using a fluorescence Microplate Reader (excitation wave length: 340 nm; emission: 460 nm). 
One unit of enzyme activity was defined as 1 nmol of 4-methylumbelliferone released per hour and 
normalized for the amount of protein contained in the lysates.
Immunofluorescence Microscopy. Immunofluorescence microscopy was performed using standard 
methods as previously described49. Cover slips were analyzed using a fluorescence microscope (Leica 
DMRE, Leica Microsystems GmbH, Wetzlar, Germany). Deconvolution studies and 3-dimensional pro-
jections were performed using a DeltaVision system (Applied Precision, Issaquah, WA) with an Olympus 
IX-71microscope. The deconvolved images were derived from optical sections taken at 30-nm intervals 
using a 60× PLAPON objective with a 1.42 numerical aperture.
Measurement of Mitochondrial Reactive Oxygen Species (ROS) Generation. Mitochondrial 
ROS generation was assessed using the mitochondrial superoxide indicator MitoSOX Red, according to 
the manufacturer’s instructions. ROS levels were expressed relative to mitochondrial mass (ROS signal/
NAO signal), determined by flow cytometry and fluorescence microscopy of cells stained with 10 μ M 
NAO for 10 minutes at 37 °C in the dark.
Measurement of Intracellular H2O2 Content. H2O2 levels were measured using non fluorescent 
CMH2-DCFDA (5-[and-6]-chloromethyl-2’,7’-dichlorodihydrofluoresceindiacetate, acetyl ester), which 
diffuses across membranes and is oxidized to fluorescent dichlorofluorescein (DCF). Cultured cells were 
rinsed in phosphate-buffered saline (PBS), incubated with CMH2-DCFDA diluted in medium at 5 μ M 
for 30 minutes at 37 °C. After that, cells were washed, trypsinized, and re-suspended in pre-warmed PBS 
at 37 °C. Cells were then analyzed by flow cytometry.
Determination of Mitochondrial Membrane Potential (ΔΨm). Cells were cultured in six-well 
35 mm plates and, at confluence, were incubated for 30 minutes with 100 nM Mitotracker Red CMXRos. 
Cells washed with fresh medium were subsequently harvested and analyzed by flow cytometry. Fibroblasts 
were grown on 1-mm width (Goldseal No. 1, Thermo Fisher Scientific Inc, Waltham, MA) glass cover-
slips for 24 to 48 hours, incubated with 100 nM MitoTracker Red for 30 minutes, fixed, and immunos-
tained with anti-cytochrome c (a mitochondrial marker), and examined by fluorescence microscopy. 
Colocalization of both markers and quantification of MitoTracker fluorescence in individual mitochon-
dria was assessed by the DeltaVision software (Applied Precision).
Mitochondria were classified as small-depolarized and tubular-polarized mitochondria (tubular, mito-
chondrial tubule of 5 μ m in length is present in a cell). When this network was disrupted and mitochon-
dria appeared predominantly spherical and small they were classified as depolarized. Quantification of 
fluorescence signal was performed in 100 cells using the ImageJ software (National Institutes of Health, 
Bethesda, Maryland, USA).
Δ Ψ m was also measured by double staining with 20 nM TMRM (a potentiometric fluorescent indi-
cator) and 100 nM MTG (a non-potentiometric dyes that relies on mitochondrial mass independent of 
Δ Ψ m) and flow cytometry analysis. Relative Δ Ψ m values were calculated by determining the ratio of 
TMRM signal to MTG fluorescence in arbitrary units.
Immunoblotting Analysis. Western blotting was performed using a standard protocol48 and the 
Immun Star HRP detection kit (Bio-Rad Laboratories Inc., Hercules, CA, USA).
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LysoTracker Red assay. LysoTracker Red (100 nM) was added to cultured fibroblasts for 30 minutes 
each, well was washed twice with fresh DMEM, and then the cells were fixed with 2% paraformaldehyde 
in PBS for 10 minutes at 4 °C. LysoTracker fluorescence was quantified by flow cytometry.
Analysis of apoptotic and viable cells. Apoptosis was assessed by observing nuclei fragmentation 
by Hoechst staining, cytochrome c release, and caspase 3 activation. Viable cells were determined from 
their normal nuclear morphology and exclusion of propidium iodide. In each case 10 random fields and 
more of 500 cells were counted.
Dot blot assay for glucosylceramide (GlcCer). Intracellular GlcCer levels was performed by a dot 
blot assays as described previously50.
Endoglycosidase-H treatment. Samples of cell lysates, containing 70 μ g of protein, were denatured 
with glycoprotein denaturing buffer (New England Biolabs 5% SDS, 0.4 M dithiothreitol) at 100 °C for 
15 minutes. The lysate was subjected to an overnight incubation with endoglycosidase-H and reaction 
buffer (New England Biolabs 0.5 M sodium citrate, pH 5.5) according to the manufacturer’s instructions. 
The lysates were then analyzed by Western blot with the anti GCase antibody.
Statistical Analysis. All results are expressed as mean± SD of 3 independent experiments. The meas-
urements were statistically analyzed using the Student’s t test for comparing 2 groups and analysis of 
variance for more than 2 groups. The level of significance was set at p < 0.05.
References
1. Platt, F. M., Boland, B. & van der Spoel, A. C. The cell biology of disease: lysosomal storage disorders: the cellular impact of 
lysosomal dysfunction. J Cell Biol 199, 723–734 (2012).
2. Grabowski, G. A. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1, 5–12 (1997).
3. Barton, B., Zauber, S. E. & Goetz, C. G. Movement disorders caused by medical disease. Semin Neurol 29, 97–110 (2009).
4. Nalls, M. A. et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 70, 727–735 
(2013).
5. Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361, 1651–1661 
(2009).
6. Westbroek, W., Gustafson, A. M. & Sidransky, E. Exploring the link between glucocerebrosidase mutations and parkinsonism. 
Trends Mol Med 17, 485–493 (2011).
7. de Pablo-Latorre, R. et al. Impaired parkin-mediated mitochondrial targeting to autophagosomes differentially contributes to 
tissue pathology in lysosomal storage diseases. Hum Mol Genet 21, 1770–1781 (2012).
8. Lebowitz, J. H. A breach in the blood-brain barrier. Proc Natl Acad Sci U S A 102, 14485–14486 (2005).
9. Schiffmann, R. et al. Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol 64, 514–522 (2008).
10. Zimran, A. & Elstein, D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos Trans R Soc Lond 
B Biol Sci 358, 961–966 (2003).
11. Benito, J. M., Garcia Fernandez, J. M. & Ortiz Mellet, C. Pharmacological chaperone therapy for Gaucher disease: a patent review. 
Expert Opin Ther Pat 21, 885–903 (2011).
12. Sawkar, A. R., D’Haeze, W. & Kelly, J. W. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher 
disease. Cell Mol Life Sci 63, 1179–1192 (2006).
13. Yoshida, H. ER stress and diseases. FEBS J 274, 630–658 (2007).
14. Tsuji, S. et al. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher’s disease. N Engl J Med 316, 570–575 
(1987).
15. Bendikov-Bar, I., Maor, G., Filocamo, M. & Horowitz, M. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. 
Blood Cells Mol Dis 50, 141–145 (2013).
16. Compain, P. et al. Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher’s 
disease. Chembiochem 7, 1356–1359 (2006).
17. Trapero, A., Gonzalez-Bulnes, P., Butters, T. D. & Llebaria, A. Potent aminocyclitol glucocerebrosidase inhibitors are subnanomolar 
pharmacological chaperones for treating gaucher disease. J Med Chem 55, 4479–4488 (2012).
18. Aguilar, M. et al. Molecular basis for β-glucosidase inhibition by ring-modified calystegine analogues. Chembiochem 9, 2612–
2618 (2008).
19. Garcia-Moreno, M. I., Benito, J. M., Ortiz Mellet, C. & Garcia Fernandez, J. M. Synthesis and evaluation of calystegine B2 
analogues as glycosidase inhibitors. J Org Chem 66, 7604–7614 (2001).
20. Alfonso, P. et al. Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher 
disease. Chembiochem 14, 943–949 (2013).
21. Aguilar-Moncayo, M. et al. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry 
disease and GM1 gangliosidosis. Chem Commun (Camb) 48, 6514–6516 (2011).
22. Rodriguez-Lavado, J. et al. Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a 
mannosylated cyclodextrin carrier. Org Biomol Chem 12, 2289–2301 (2014).
23. García Fernández, J. M., Ortiz Mellet, C., Benito Hernandez, J. M. & Fuentes Mota, J. Synthesis of calystegine B2 analogs by 
tandem tautomerization-intramolecular glycosylation of thioureidosugars. Synlett 3 316–318 (1998).
24. Ebadi, M. et al. Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of parkinson’s disease. Biol Signals Recept 10, 
224–253 (2001).
25. Matalonga, L. et al. Treatment effect of coenzyme Q and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. 
J Inherit Metab Dis 37, 439–446 (2014).
26. Haas, R.H. et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 94, 16–37 (2008).
27. Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T. & Thompson, C. B. Bcl-xL regulates the membrane 
potential and volume homeostasis of mitochondria. Cell 91, 627–637 (1997).
28. Scherz-Shouval, R. & Elazar, Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci 36, 30–38 (2011).
29. Garrido-Maraver, J. et al. Clinical applications of coenzyme Q10. Front Biosci (Landmark Ed) 19, 619–633 (2014).
30. Lieberman, A. P. et al. Autophagy in lysosomal storage disorders. Autophagy 8, 719–730 (2012).
www.nature.com/scientificreports/
1 8Scientific RepoRts | 5:10903 | DOi: 10.1038/srep10903
31. Kim, I., Rodriguez-Enriquez, S. & Lemasters, J. J. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 
462, 245–253 (2007).
32. Schroder, B. A., Wrocklage, C., Hasilik, A. & Saftig, P. The proteome of lysosomes. Proteomics 10, 4053–4076 (2010).
33. Ezaki, J., Wolfe, L. S. & Kominami, E. Specific delay in the degradation of mitochondrial ATP synthase subunit c in late infantile 
neuronal ceroid lipofuscinosis is derived from cellular proteolytic dysfunction rather than structural alteration of subunit c. J 
Neurochem 67, 1677–1687 (1996).
34. Green, D. R., Galluzzi, L. & Kroemer, G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. 
Science 333, 1109–1112 (2011).
35. Farfel-Becker, T. et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to 
neurodegeneration. Hum Mol Genet 23, 843–854 (2014).
36. Strasberg, P. Cerebrosides and psychosine disrupt mitochondrial functions. Biochem Cell Biol 64, 485–489 (1986).
37. Osellame, L. D. et al. Mitochondria and quality control defects in a mouse model of Gaucher disease–links to Parkinson’s disease. 
Cell Metab 17, 941–953 (2013).
38. Sentelle, R. D. et al. Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol 8, 831–838 
(2012).
39. Fuller, M. et al. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher 
disease. Mol Genet Metab 93, 437–443 (2008).
40. Mitsui, J. et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 66, 571–576 (2009).
41. Parenti, G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 1, 
268–279 (2009).
42. Boyd, R. E. et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 56, 2705–2725 (2013).
43. Artuch, R. et al. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Neuropediatrics 35, 95–98 (2004).
44. Mizushima, N. et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 152, 
657–668 (2001).
45. Aguilar-Moncayo, M. et al. Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in 
their pharmacological chaperone potential towards β-glucocerebrosidase. Org Biomol Chem 9, 3698–3713 (2011).
46. Rustin, P. et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 228, 35–51 (1994).
47. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. J Biol Chem 
193, 265–275 (1951).
48. Rodriguez-Hernandez, A. et al. Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy 5, 19–32 
(2009).
49. Cotan, D. et al. Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. 
FASEB J 25, 2669–2687 (2011).
50. Brade, L., Vielhaber, G., Heinz, E. & Brade, H. In vitro characterization of anti-glucosylceramide rabbit antisera. Glycobiology 10, 
629–636 (2000).
Acknowledgements
This work was supported by the Spanish Ministerio de Sanidad (FIS PI13/00129 grant), the Spanish 
Ministerio de Economía y Competitividad (contract numbers SAF2013-44021-R and CTQ2010-15848), 
the Junta de Andalucía (Proyectos de Investigación de Excelencia CTS-5725 and FQM-1467), the Fondo 
Europeo de Desarrollo Regional (FEDER-Unión Europea), the Fondo Social Europeo (FSE), by AEPMI 
(Asociación de Enfermos de Patología Mitocondrial) and by Mehuer Foundation.
Author Contributions
M.D.M., J.A.S.A. designed research and wrote the paper; M.D.M., D.C., M.O.A., J.G.M., M.V.P., A.F.P., 
I.D.L. and A.D.P. performed research; M.D.C., P.Y.G. and E.A.G. analyzed data; A.P.Z., C.O.M. and 
J.M.G.F. contributed new reagents or analytic tools.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: de la Mata, M. et al. Pharmacological Chaperones and Coenzyme Q10 
Treatment Improves Mutant ß-Glucocerebrosidase Activity and Mitochondrial Function in 
Neuronopathic Forms of Gaucher Disease. Sci. Rep. 5, 10903; doi: 10.1038/srep10903 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
